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context: Cortisol has been suggested as a risk factor for choroidal thickening, which 
may lead to retinal changes.
Objective: To compare choroidal thickness measurements using optical coherence 
tomography (OCT) in patients with endogenous active Cushing’s syndrome (CS) and to 
evaluate the occurrence of retinal abnormalities in the same group of patients.
Design: Cross-sectional study.
setting: Outpatient clinic.
Patients: Eleven female patients with CS in hypercortisolism state as determined by 
the presence of at least two abnormal measurements from urinary cortisol 24  h, no 
suppression of cortisol with low dose dexamethasone suppression test, and nocturnal 
salivary cortisol levels and 12 healthy controls.
Methods: Choroidal and retinal morphology was assessed using OCT.
Main outcome measures: Choroidal thickness measurements and the presence of 
retinal changes.
results: The mean subfoveal choroidal thickness was 372.96  ±  73.14  µm in the 
patients with CS and 255.63 ± 50.70 µm in the control group (p < 0.001). One patient 
(9.09%) presented with central serous chorioretinopathy and one patient (9.09%) with 
pachychoroid pigment epitheliopathy.
conclusion: Choroidal thickness is increased in the eyes of patients with active CS 
compared to healthy and matched control. Also, 18.18% of patients presented with 
macular changes, possibly secondary to choroidal thickening. While further studies are 
necessary to confirm our findings, excess corticosteroid levels seem to have a significant 
effect on the choroid and might be associated with secondary retinal diseases.
Keywords: hypercortisolism, cushing syndrome, choroid, optical coherence tomography, eye
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inTrODUcTiOn
Endogenous Cushing’s syndrome (CS) is a prototype of metabolic 
syndrome due to chronic exposure to excess cortisol. The clini-
cal presentation varies depending mostly on the time span the 
patient is submitted to excessive cortisol production and is char-
acterized by weight gain, facial plethora, central obesity, proximal 
muscle weakness, hypertension, diabetes mellitus, osteoporosis, 
neuropsychological disturbances, and purple striae (1).
Several previous reports have documented visual loss in 
endogenous CS resulting from central serous chorioretinopathy 
(CSC), a disease that impairs central vision and is characterized 
by serous retinal detachment, retinal pigment epithelium (RPE) 
changes, and choroidal vascular hyperpermeability (2–4). While 
the pathogenesis of CSC is still poorly understood, several risk 
factors seem to be involved such as younger age, male gender, 
type-A behavioral pattern, history of organ transplant, pregnancy, 
systemic blood hypertension, use of exogenous corticosteroids, 
and endogenous hypercortisolism (5–7).
The mechanisms by which corticosteroids are implicated in 
the development of CSC are unclear. Currently, it is believed that 
cortisol excess may lead to a number of choroid abnormalities 
including (a) increased capillary fragility, leading to choroidal 
circulation imbalance and leakage of fluid to the subretinal space; 
(b) blood coagulation in the choroid, leading to choroidal hypop-
erfusion; (c) inhibition of collagen formation affecting the main 
component of Bruch’s membrane, the innermost choroid layer; 
(d) impact on ion and water transport of epithelial cells through 
interference on mineralocorticoid receptors; and (e)  induce 
systemic hypertension, which in itself is a risk factor for CSC (7).
The choroid is primarily a vascular tissue, which provides 
the major blood supply to the retina. It can be assessed by two 
different methods: indocyanine green angiography (ICG), which 
is a somewhat invasive method, and by enhanced depth image 
optical coherence tomography (EDI-OCT), a non-invasive exam. 
Patients with CSC often present choroid vascular hyperperme-
ability on ICG and increased choroidal thickness when measured 
by EDI-OCT (8–11).
Several reports have reported increased choroidal thickness 
in both affected and fellow eyes of CSC patients, compared to 
control subjects. Moreover, in cases of unilateral CSC, the affected 
eye seems to be thicker than the fellow eye (12–14).
Because of the previous association of CSC both with excess 
corticosteroid levels and choroidal thickening, we hypothesized 
that patients with endogenous hypercortisolism might develop 
choroidal thickening that could be a predisposing factor for CSC 
and other diseases possibly associated to choroidal thickening 
such as pachychoroid pigment epitheliopathy (PPE), pachycho-
roid neovasculopathy (PN), and polypoidal choroidal vasculopa-
thy (PCV) (15, 16).
More recently, Karaca et  al. reported a thicker choroid in 
patients with CS possibly related to increased levels of ACTH 
itself, increased levels of plasma cortisol, or both (17). Therefore, 
the aim of the present study was to evaluate possible effects 
of excess corticosteroids exposure on choroidal thickness using 
OCT and to investigate possible retinal abnormalities in patients 
with active hypercortisolism due to endogenous CS.
MaTerials anD MeThODs
This cross-sectional study was performed at the Division of 
Ophthalmology and the Department of Endocrinology of the 
University of São Paulo Medical School. The study was approved 
by our institutional review board and conducted according to the 
Declaration of Helsinki. Informed written consent was obtained 
from all participants.
A diagnosis of active CS was established by the presence 
of at least two unequivocal altered of first line screening for 
CS [urinary cortisol (UC) 24  h, nocturnal serum, or salivary 
cortisol] and serum cortisol (Fs) after low dose dexamethasone 
suppression test (Fs > 1.8 μg/dL or 50 mmol/L). Eleven patients 
were selected for the study, nine due to ACTH-dependent and 
two due to ACTH-independent CS. Twelve healthy patients were 
recruited as a control group, matched for age and gender to the 
patients. Control patients with systemic diseases, like arterial 
systemic hypertension, diabetes, autoimmune diseases, or any 
other condition that could affect the choroid and retina were 
excluded. Moreover, those undertaking exogenous steroids in 
either anti-inflammatory or immunosuppressive dose in the past 
12 months were also excluded.
Considering that CSC can be present unilaterally, both eyes 
were included. Exclusion criterion for patients were the presence 
of refractive error exceeding ±6.00 diopters (D) of spherical 
equivalent, presence of more than two diopters of keratometric 
astigmatism, axial length of more than 26.5 mm, important media 
opacity (resulting in poor OCT image quality), history of uveitis 
and retinal diseases other than CSC, and any choroidal-related 
diseases, such as PPE, PN, and PCV. Patients with a history of 
glaucoma or any other optic neuropathy, intraocular surgery in 
the past 3 months (including cataract surgery), intravitreal injec-
tions (steroids and/or anti-vascular endothelial growth factor), 
and/or laser treatment were also excluded.
Patient assessment
All patients were submitted to a comprehensive ocular examina-
tions, including biomicroscopy of anterior and posterior segments, 
indirect fundoscopy, axial length measurement (IOL Master, Carl 
Zeiss, Jena, Germany), and spectral-domain optical coherence 
tomography (SD-OCT) (Spectralis; Heidelberg Engineering, 
Heidelberg, Germany) with an EDI protocol (horizontal and ver-
tical scans, 7 sections, high resolution mode, 25 frames). SD-OCT 
images were routinely obtained at the same time, avoiding diur-
nal variations of choroidal vasculature. Two raters experienced 
in examining EDI-OCT images (Maria Fernanda Abalem and 
Helen Nazareth Veloso Dos Santos) independently evaluated the 
choroidal features. The third rater (Pedro Carlos Carricondo) was 
consulted when the two raters disagreed.
choroidal evaluation
The following features were addressed, as described previously 
(10, 18):
(A) Total choroidal thickness (TCT) was measured at the 
subfoveal position. The measures were performed manually 
using the caliper of the Eye Explorer software (v. 6.0.9.0; 
TaBle 1 | clinical and hormonal data of cushing’s syndrome patients.
N Patient age  
(years old)
gender Uc 24 h  
(μg/24 h)
acTh  
(pg/ml)
etiology Pituitary  
Mri
active hypercortisolism 
state (months)
1 APS 33 Female 837a 126.2 CD MICRO 115
2 DPM 22 Female 502a 42.5 CD MACRO 28
3 FSF 32 Female 399b 126.8 CD MACRO 90
4 LLA 35 Female 1288a 42.2 CD MICRO 5
5 MLP 51 Female 826a 42.2 CD MACRO 38
6 MISO 45 Female 1485a 87.1 CD MICRO 15
7 PRM 29 Female 371a 33.2 CD MICRO 80
8 SAGP 26 Female 334b 77.5 CD MACRO 18
9 VAS 69 Female 295a/0.8c <2.0 CS – 360
PMAH
10 GMS 19 Female 982a <2.0 CS – 48
Adenoma
11 VLCL 62 Female 733a <2.0 CS – 12
Carcinoma
UC, urinary cortisol 24 h (normal range: aReference: 50–310 μg/24 h or bReference: 3–43 μg/24 h); cMidnight salivary cortisol (normal value: up to 0.12 μg/dL); ACTH (normal range: 
7.2–63.30 pg/mL); CD, Cushing’s disease; CS, Cushing’s syndrome; PMAH, primary macronodular adrenal hyperplasia; MRI, magnetic resonance imaging; MICRO (microadenoma 
<10 mm); MACRO (macroadenoma ≥10 mm) based on MRI.
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Heidelberg Engineering) with 80% zoom. The measure was 
obtained perpendicularly, from the outer edge of the hyper-
reflective RPE to the hyperreflective inner sclera.
(B) Choroidal segmentation: three large choroidal vessels 
measuring at least 100  μ in diameter, located subfoveal, 
and a perpendicular line from the innermost point of each 
one was drawn so these lines would intersect with the lines 
used to measure TCT. The Haller layer was determined by 
measuring perpendicularly from the inner border of the 
sclera to the innermost line of the selected large choroidal 
vessels. The remaining distance of choroidal thickness was 
considered as the choriocapillaris/Sattler layer complex. 
These two layers were analyzed together because current 
OCT technology still does not allow for the separation of 
both layers.
retinal evaluation
The main characteristics of CSC, PPE, PN, and PCV were 
addressed, including the presence of subretinal fluid, intraretinal 
cysts, ellipsoid layer disruption, drusen, pigmented epithelium 
detachment, and choroidal neovascularization.
statistical analysis
All statistical analyses were performed using the SPSS software 
version 18.0 (SPSS, Chicago, IL, USA). Numerical values were 
reported as mean ± SD. Choroidal thickness parameters, includ-
ing the thickness of Haller layer, the choriocapillaris/Sattler layer 
were estimated and compared. The interobserver reliability was 
expressed as the intraclass correlation coefficient. Also, p values 
of 0.05 were considered statistically significant.
Optical coherence tomography measurements of both eyes 
were compared by using Generalized Estimating Equation (GEE) 
models, in order to compensate inter-eye dependencies. In this 
study, all patients and controls had both eyes included. As eyes 
of the same individual were expected to have some degree of 
intercorrelation with respect to OCT parameters, GEE models 
were used to adjust for within-patient inter-eye correlations. GEE 
models are generalized linear models that allow for the specifica-
tion of within-group correlations when evaluating the ability 
of one or several independent variables to predict a dependent 
variable.
resUlTs
From 2010 to 2015, a total of 11 patients with active endogenous 
CS, mean age of 38.45 years (±16.32), and 12 control patients, 
mean age of 51.33 years (±16.64), were included in this study. By 
chance, all of them were female subjects. There was no statistical 
difference between age of patients and controls (p = 0.08). The eti-
ologies of CS were eight patients with (72.7%) Cushing’s disease 
(pituitary adenoma), one (9.1%) with adrenocotical adenoma, 
one (9.1%) with adrenocortical carcinoma, and one (9.1%) with 
primary macronodular adrenal hyperplasia (PMAH). None of 
our patients had pituitary tumor with suprasellar extension as 
confirmed by magnetic resonance imaging. As required to be 
eligible, all patients were in hypercortisolism state according to 
UC 24 h levels and nocturnal salivary cortisol (patient number 
9) (Table 1). No control patient presented with any autoimmune 
and/or vascular systemic and ocular condition as required to be 
included in this study. However, one patient had prior history 
of breast cancer diagnosed and surgically treated 10 years ago, 
and two patients had prior history of cholecystectomy in the past 
5 years due to chronic cholecystitis. Any patient had history of 
exogenous steroids intake in the past 12 months (Table 2).
The interobserver reliability of the two retinal specialists who 
performed the measurements was very good. The intraclass cor-
relation coefficients were of 0.876 for TCT, 0.864 for the thickness 
of Haller layer, and 0.996 for the choriocapillaris/Sattler layer.
The mean subfoveal choroidal thickness was 372.96 ± 73.14 µm 
in eyes of patients with CS and 255.63 ± 50.70 µm in eyes of the 
control group, with statistically significant difference (p < 0.001, 
GEE) (Figure 1). The results were similar in the mean thickness 
TaBle 2 | Demographical and clinical data of control patients.
N Patient age (years) gender comorbidities
1 MEGB 27 Female No
2 APP 27 Female No
3 MS 29 Female No
4 CSS 43 Female No
5 NAO 51 Female No
6 ESL 54 Female Cholescystitisa
7 DMC 55 Female Breast cancera
8 HHR 60 Female No
9 MHGK 60 Female Cholescystitisa
10 ESG 65 Female No
11 VB 68 Female No
12 ANB 77 Female No
aSurgically treated.
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of Haller layer, measuring 342.05 ± 73.77 µm in eyes of patients 
with CS and 231.92 ±  51.54  µm in eyes of the control group 
(p < 0.001, GEE). The mean thickness of choriocapillaris/Sattler 
layer also was statistically different, measuring 34.91 ± 22.36 µm 
in the group with CS and 23.71 ± 14.93 µm in the control group 
(p < 0.001, GEE).
Two patients (18.18%) presented with macular changes. 
Patient 1 presented drusen-like lesions, associated with ellipsoid 
zone irregularity on both eyes, suggesting PPE. Patient 10 pre-
sented with bilateral subretinal fluid, associated to ellipsoid zone 
irregularity and drusen-like lesions, suggestive of CSC (Figure 2).
DiscUssiOn
Cushing’s syndrome is a medical condition that can be associated 
with numerous deleterious changes in various organ systems 
leading to comorbidities and increased mortality ratio. This study 
addressed possible effects of excessive corticosteroid levels on the 
choroid in patients with active hypercortisolism due to endog-
enous CS. We have found that TCT was significantly greater in 
patients with endogenous CS, when compared with age- and 
gender-matched controls, without any history of systemic and 
ocular vascular or autoimmune condition that could directly or 
indirectly affect both retina and choroid as well as prior history 
of exogenous steroids intake in the past 12 months.
Our findings are in agreement with a number of previous 
studies, which demonstrated a thicker choroid in patients with 
CSC, a condition that is also related to elevated systemic levels 
of corticosteroids. Several reports identified corticosteroids as 
a significant risk factor for the development of acute, exudative 
macular manifestation in patients with CSC, either by endogenous 
Cushing syndrome or by exogenous intake (2, 7, 19, 20). Garg 
et al. also demonstrated an increase in the 8:00 a.m. and 11:00 
p.m. serum cortisol and UC 24  h levels in acute CSC patients 
compared to healthy subjects (21, 22).
Additionally, other endocrine abnormalities were found 
in a case series of 24 patients with CSC, such as UC 24 h and 
tetrahydroaldosterone levels, low serum aldosterone levels, 
elevated single morning plasma catecholamine level, but normal 
24-h urine metanephrines (23). The current study is partially in 
accordance with a recent study by Karaca et al. that encountered 
an association between choroidal thickening and ACTH levels in 
patients with chronic CS, suggesting that ACTH itself, increased 
cortisol levels, or both might be related to this finding (17). 
However, in this study it is not clear about the cortisol state of 
patients because only the midnight and morning serum cortisol 
were evaluated. It is possible that these patients had only absence 
of circadian secretion due to medical treatment (e.g., cabergoline, 
ketoconazole, or pasireotide) in the presence of normal levels of 
UC 24 h (24). The total cortisol secretion measured by UC 24 h 
should have been demonstrated to characterize hypercortisolism 
activity. Moreover, to the best of our knowledge, there are no 
melanocortin receptors on the choroid; hence, it seems more 
likely that increased cortisol levels may be responsible for the 
choroidal changes.
The choroid can change their volume, thereby their thick-
ness as much as fourfold over a few days. There are five possible 
mechanisms underlying choroidal thickening. The most likely 
mechanism is due to the synthesis of osmotically active molecules 
that act as “sponges” leading to expansion of the lacunae (25). 
Another mechanism refers to changes in vascular permeability. 
An increase in capillary permeability may allow proteins to move 
into the extracellular matrix and/or lymphatic, followed by pas-
sive fluid flow (26). A third mechanism proposed derives from the 
aqueous humor flow from the anterior chamber to the choroid. 
Since the choroid is part of the uveoscleral outflow pathway, an 
increase in the humor aqueous flow may be transmitted to the 
choroid and expand it (25, 27). Another similar mechanism is 
by moving fluid across the RPE. There is a flow of ions and water 
between the retina and the choroid, and changes in this flow 
might impact on choroidal thickness (28). Finally, the choroid 
may thicken because of changes in the tonus of non-vascular 
smooth muscle cells that are controlled by both sympathetic 
and parasympathetic inputs. If these cells relax, the choroid may 
become thicker (29–31).
The excess of cortisol has several effects that may be involved 
in the mechanisms that modulate choroidal thickness contrib-
uting for both thickening and thinning. Corticosteroids may 
increase osmolarity and active fluid flow into the choroidal vas-
culature (32); increase renal tubular sodium reabsorption and 
intravascular volume expansion (33); dilate choroidal endothe-
lial cells (33, 34); and inhibit the formation of collagen, which 
may facilitate moving fluid across the RPE (7). On the other 
side, corticosteroids impair vasodilation, induce vasoconstric-
tion (also by enhancement of the renin angiotensin system), 
and increase the vascular sensitivity to the effects of catecho-
lamines (33). These effects are thought to thin the choroid. We 
believe the thickening mechanisms have predominated because 
thinning is somewhat limited by mechanical restrictions and 
because intravascular expansion may lead to expansion of 
the lacunae, which is the major anatomical change, related to 
choroidal thickening (31).
In the current study, the Haller layer thickness was greater 
in patients with CS than in controls. The choriocapillaris/Sattler 
layer complex did not show any difference in both groups. These 
findings suggest that increased TCT was at least in part due to 
increased Haller layer thickness. Chung et al. also assessed the 
Haller and Sattler layers in patients with CSC and showed a 
FigUre 1 | enhanced depth image optical coherence tomography scans. (a) Patient with Cushing’s syndrome. (B) Control patient. The caliper (green) 
represents the choroidal thickness. The arrowheads represent the anterior boundary of the sclera.
5
Abalem et al. Choroidal and Retinal Changes in Cushing Syndrome
Frontiers in Endocrinology | www.frontiersin.org December 2016 | Volume 7 | Article 154
greater ratio of Haller layer/TCT. They believed these findings 
were possibly due to the higher number of non-vascular smooth 
muscle cells in the Haller layer, which may stretch out, leading 
to vascular dilation and accumulation of fluid in the stroma. 
Alternatively, the lower number of these cells in the choriocapil-
laris/Sattler layers might keep these layers relatively stable under 
sympathetic stimuli (10). Furthermore, the lacunae are more 
predominant and larger in the suprachoroid, which may explain 
a greater vascular expansion in this location (31).
Han et al. prospectively evaluate the effects of corticosteroids 
on choroidal thickness in patients who required high-dose 
corticosteroid pulse therapy for a short period, with a 1-month 
follow-up (35). While the authors did not find changes in choroi-
dal thickness, they described some features of CSC like pigment 
epithelial detachment and subretinal fluid in one patient who also 
presented with a thicker choroid. This lack of consistent changes 
might be explained by the fact that these patients were under 
high levels of cortisol, but for a short period. In our study, all 
FigUre 2 | Macular optical coherence tomography scans. (a) Left eye of patient 1 with drusen-like lesions, associated with ellipsoid zone irregularity and 
choroidal thickening. (B) Right eye of patient 10 with subretinal fluid (arrow), associated to ellipsoid zone irregularity and choroidal thickening.
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patients were under prolonged and excessive cortisol exposure, 
suggesting that choroidal thickening also depend on both factors: 
degree and duration of hypercortisolism, as occurs with systemic 
manifestations (35).
We also found one patient (9.09%) with a PPE and another 
(9.09%) with bilateral CSC, conditions that were demonstrated to 
be associated with choroidal thickening (10, 15). The frequency of 
PPE in overall population is still unknown. It is a misdiagnosed 
condition, in which there is a marked disturbance in the RPE 
cells with possible visual impairment (15). According to Bouzas 
et al., the incidence of CSC is 5% in patients with endogenous 
CS. In this study, 3 out of 46 women and 1 out of 14 men were 
affected (2). We believe this condition might be underestimated 
in patients with CS, because (1) during the hypercortisolism state, 
the patient and the physician might not note this kind of symptom 
and (2) CSC is self-limited in most cases and visual acuity usually 
returns to 20/25 or better (36, 37), although chronic and atypical 
cases may also occur in 30–50% of cases (7, 38, 39). Thus, we 
believe patients with CS might require proper retinal evaluation.
To our knowledge, this is the first study to describe choroidal 
and retinal abnormalities in patients with active endogenous 
CS-dependent and independent of ACTH during hypercorti-
solism state, based on high levels of UC 24 h, except in the patient 
with PMAH, where cortisol activity was characterized based on 
both midnight salivary cortisol and low dose dexamethasone 
suppression test. As increased cortisol activity is the hallmark of 
CS, this specific group of patients provides better understanding 
of the effects of cortisol on the choroid. We believe the increased 
osmolarity, the mineralocorticoid effects of cortisol, and the 
activation of the renin angiotensin system in patients with CS 
may be involved in the pathophysiology of choroidal expansion 
explaining the increased choroidal thickness measurements.
The current study has a number of limitations including 
the cross-sectional design and the small number of patients. 
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However, our data serve to emphasize the existence of an 
additional morbidity in patients with endogenous CS. Further 
comparative studies are therefore required to better evaluate 
(1) the role of other adrenal hormones, such as catecholamines 
that also seem to be involved in the pathogenesis of CSC (40, 
41); (2) the long-term effects of cortisol on both the choroid 
and the retina of these patients; and (3) the visual impairment 
caused by such abnormalities. Since choroidal thickening is 
associated to retinal conditions, like CSC, PPE, PN, and PCV, 
patients with CS in hypercortisolism state should be evaluated 
for these conditions.
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